Allergan Presents New Data at the American Urological Association Meeting in San Diego

DUBLIN, May 3, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that it has presentations in overactive bladder, nocturia and ulcerative interstitial cystitis at the upcoming American Urological Association (AUA) annual meeting in San Diego, California, May 6-10.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

The scheduled times (noted in local Pacific Time) of the presentations and room locations at the San Diego Convention Center are as follows:

• "Real-World Clean Intermittent Catheterization Rates After Treatment with OnabotulinumtoxinA in Patients with Overactive Bladder"
  • Moderated Poster - MP74; Room 24
  • Authors: Kennelly M, Green L, Fathali N, Wehbe S, Smith J, MacDiarmid S,  Mangel J, Schwartz M, Aboushwareb T,  Murray B
  • Monday, May 9^th, 1:00 - 3:00 PM
• "A Randomized, Double-Blind, Placebo Controlled Study of 2 Doses of SER120 Nasal Spray in Patients with Nocturia" (conducted by development partner Serenity Pharmaceuticals LLC)
  • Moderated Poster - MP74; Room 24
  • Authors: Kaminetsky J, Wein A, Dmochowski R, Herschkowitz S, Cheng M, Abrams S, Fein S
  • Monday, May 9^th, 1:00 - 3:00 PM
• "Consistent and Durable Improvements in Quality of Life with Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder"
  • Moderated Poster - MP74; Room 24
  • Authors: Ginsberg D, Drake M, Kaufmann A, Radomski S, Gousse A, Magyar A, Nicandro J, Nitti V
  • Monday, May 9^th, 1:00 - 3:00 PM
• "OnabotulinumtoxinA Treatment Results in Greater Reductions in Urinary Incontinence in Patients With Overactive Bladder Compared With Solifenacin or Placebo"
  • Moderated Poster - MP72; Room 24
  • Authors: Herschorn S, Kohan A, Aliotta P, McCammon K, Sriram R, Abrams S, Lam W, Everaert K      
  • Monday, May 9^th, 1:00 - 3:00 PM
• "Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial Cystitis"
  • Moderated Poster - MP72; Room 31
  • Authors: Peters K, Seifu Y, Cutie C, Radecki  D
  • Monday, May 9^th, 1:00 - 3:00 PM

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

SOURCE Allergan plc

Related Links

http://www.allergan.com